Search

Your search keyword '"R. Laguna"' showing total 188 results

Search Constraints

Start Over You searched for: Author "R. Laguna" Remove constraint Author: "R. Laguna"
188 results on '"R. Laguna"'

Search Results

151. [No to self medication].

152. The search for a curative cell therapy in Parkinson's disease.

153. Total hip arthroplasty in paralytic dislocation from poliomyelitis.

154. 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.

155. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.

156. The future of cell therapies in the treatment of Parkinson's disease.

157. Western blot antibody determination in sera from patients diagnosed with Anisakis sensitization with different antigenic fractions of Anisakis simplex purified by affinity chromatography.

158. ELISA antibody determination in patients with anisakiosis or toxocariosis using affinity chromatography purified antigen.

159. Identification of the DNA bases of a DNase I footprint by the use of dye primer sequencing on an automated capillary DNA analysis instrument.

160. Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.

161. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes.

162. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones.

163. Cross-reactivity between Anisakis simplex sensitization and visceral larva migrans by Toxocara canis.

164. Pyridazines. Part 31: synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones.

165. Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions.

166. Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors.

167. Purification of Anisakis simplex antigen by affinity chromatography.

168. Induction of phase variation events in the life cycle of the marine coccolithophorid Emiliania huxleyi.

169. Vertebral hemangioma mimicking a metastatic bone lesion in well-differentiated thyroid carcinoma.

170. Specific and total IgE in patients with recurrent, acute urticaria caused by Anisakis simplex.

171. Pyridazines. XVIII. 6-Aryl-3(2H)-pyridazinones inhibit calcium influx in stimulated platelets.

172. AM1 theoretical study, synthesis and biological evaluation of some benzofuran analogues of anti-inflammatory arylalkanoic acids.

173. Technetium-99m-MAG3 in early identification of pyelonephritis in children.

174. Indications for use of the long Gamma nail.

175. Osteochondritis dissecans of the talus during childhood and adolescence.

176. Thrombomodulin modulates the mitogenic response to thrombin of human umbilical vein endothelial cells.

177. Pyridazines. XIII. Synthesis of 6-aryl-5-oxygenated substituted-3(2H)-pyridazinones and evaluation as platelet aggregation inhibitors.

178. Clinical tolerance, parasitological efficacy and environmental effects of dehumidifiers in stable asthmatics sensitized to house dust mites.

179. Serum levels of eosinophil cationic protein and eosinophil protein x in pollen atopic patients with stable asthma and its relation with bronchial hyperresponsiveness.

180. Anaphylaxis induced by ingestion of a pollen compound.

181. Scintigraphic findings in a Brodie's abscess.

182. [Cytologic and biochemical component in 203 bronchoalveolar lavages. Reference values].

183. Tumour markers in broncho-alveolar lavage.

184. [Acute lymphocytic leukaemia with erythrophagocytic activity (author's transl)].

185. [Diagnostic importance of the mouse erythrocyte receptor in lymphoproliferative syndromes].

186. Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL.

187. [Behavior of leukocyte chemotaxis in various clinico-immunological situations].

188. Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia.

Catalog

Books, media, physical & digital resources